San Diego, CA, United States of America

Stephane Billotte


Average Co-Inventor Count = 6.0

ph-index = 1

Forward Citations = 2(Granted Patents)


Location History:

  • Kent, GB (2002)
  • San Diego, CA (US) (2005)

Company Filing History:


Years Active: 2002-2005

Loading Chart...
2 patents (USPTO):Explore Patents

Title: The Innovative Contributions of Stephane Billotte

Introduction

Stephane Billotte is a notable inventor based in San Diego, CA. He has made significant contributions to the field of biochemistry, particularly in the development of compounds that have therapeutic applications. With a total of 2 patents, his work focuses on innovative solutions for medical conditions.

Latest Patents

Among his latest patents is the invention of 3-heterocyclylpropanohydroxamic acids. These compounds, along with their salts, solvates, and prodrugs, serve as Procollagen C-Proteinase (PCP) inhibitors. They are designed to address conditions mediated by PCP, showcasing the potential for impactful medical treatments.

Career Highlights

Stephane has worked with prominent companies in the pharmaceutical industry, including Pfizer Corporation and Pfizer Products Inc. His experience in these organizations has allowed him to contribute to significant advancements in drug development and therapeutic solutions.

Collaborations

Throughout his career, Stephane has collaborated with talented individuals such as Simon Bailey and Andrew Michael Derrick. These partnerships have fostered a creative environment that has led to innovative discoveries and advancements in their respective fields.

Conclusion

Stephane Billotte's work exemplifies the spirit of innovation in the pharmaceutical industry. His patents and collaborations highlight his commitment to developing solutions that can improve health outcomes. His contributions continue to inspire future advancements in medical research and development.

This text is generated by artificial intelligence and may not be accurate.
Please report any incorrect information to support@idiyas.com
Loading…